Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020 Read more about Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020 Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update Read more about Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 Read more about Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 Iovance Biotherapeutics to Present at Upcoming June Conferences Read more about Iovance Biotherapeutics to Present at Upcoming June Conferences Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program Read more about Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma Read more about Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020 Read more about Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update Read more about Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 Read more about Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
Iovance Biotherapeutics to Present at Upcoming June Conferences Read more about Iovance Biotherapeutics to Present at Upcoming June Conferences
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program Read more about Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma Read more about Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma Read more about Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
